{"entity":{"id":"judy-garber","kind":"person","name":"Judy E. Garber","aka":[],"tldr":"A leading authority on inherited cancer risk and how BRCA carriers should be treated and screened.","summary":"Judy E. Garber is Chief of the Division of Cancer Genetics and Prevention and holds the Susan F. Smith Chair at Dana-Farber Brigham Cancer Center. She is a leading authority on inherited cancer risk and on how BRCA carriers should be treated and screened, having contributed to the TBCRC neoadjuvant cisplatin trials in BRCA-associated breast cancer and to the OlympiA trial. Her selected paper reports adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. She directs cancer genetics and prevention at Dana-Farber, spanning germline testing, chemoprevention and risk-reducing surgery.","asOf":"2026-09-08","links":[{"label":"Dana-Farber profile","url":"https://www.dana-farber.org/find-a-doctor/judy-e-garber"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Garber%20JE%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["tnbc","breast-hr-positive","ovarian"],"sections":[],"technologies":["germline-testing","chemoprevention"],"targets":["brca"],"drugs":[],"companies":[],"institutions":["dana-farber"],"pathways":[],"terms":[],"trials":["olympia"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief, Division of Cancer Genetics and Prevention; Susan F. Smith Chair","institutionId":"dana-farber","specialisms":["Hereditary cancer","BRCA1/2","Cancer prevention"],"profiles":[{"label":"Dana-Farber profile","url":"https://www.dana-farber.org/find-a-doctor/judy-e-garber"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Garber%20JE%5BAuthor%5D"}],"papers":[{"title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","journal":"New England Journal of Medicine","year":2021,"url":"https://doi.org/10.1056/NEJMoa2105215","doi":"10.1056/NEJMoa2105215"}],"orcid":"0000-0001-9449-3982"},"route":"/people/judy-garber/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"technology":[{"id":"chemoprevention","kind":"technology","name":"Chemoprevention & risk-reducing surgery","route":"/technologies/chemoprevention/"},{"id":"germline-testing","kind":"technology","name":"Germline (hereditary) testing","route":"/technologies/germline-testing/"}],"target":[{"id":"brca","kind":"target","name":"BRCA1 / BRCA2 (HRD)","route":"/targets/brca/"}],"institution":[{"id":"dana-farber","kind":"institution","name":"Dana-Farber Brigham Cancer Center","route":"/institutions/dana-farber/"}],"trial":[{"id":"olympia","kind":"trial","name":"OlympiA","route":"/trials/olympia/"}],"paper":[{"id":"paper-olympia-nejm-2021","kind":"paper","name":"OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer","route":"/key-papers/paper-olympia-nejm-2021/"},{"id":"paper-olympia-overall-survival-ann-oncol-2022","kind":"paper","name":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer","route":"/key-papers/paper-olympia-overall-survival-ann-oncol-2022/"},{"id":"paper-olympia-6-year-update-ann-oncol-2026","kind":"paper","name":"Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trial","route":"/key-papers/paper-olympia-6-year-update-ann-oncol-2026/"}],"roadmap":[{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/"}],"person":[{"id":"angelina-jolie","kind":"person","name":"Angelina Jolie","route":"/people/angelina-jolie/"},{"id":"mary-claire-king","kind":"person","name":"Mary-Claire King","route":"/people/mary-claire-king/"}]}}